🇺🇸 ch14.18 -NCI in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 11

Most-reported reactions

1. Urinary Retention — 2 reports (18.18%)
2. Ascites — 1 report (9.09%)
3. Atonic Urinary Bladder — 1 report (9.09%)
4. Bladder Dilatation — 1 report (9.09%)
5. Influenza Like Illness — 1 report (9.09%)
6. Necrotising Colitis — 1 report (9.09%)
7. Neuropathy Peripheral — 1 report (9.09%)
8. Pneumatosis Intestinalis — 1 report (9.09%)
9. Portal Venous Gas — 1 report (9.09%)
10. Pyelocaliectasis — 1 report (9.09%)

Source database →

Frequently asked questions

Is ch14.18 -NCI approved in United States?

ch14.18 -NCI does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ch14.18 -NCI in United States?

United Therapeutics is the originator. The local marketing authorisation holder may differ — check the official source linked above.